Revision 1

Store at -20C

#4885

FUS/TLS Antibody

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source:	UniProt ID:	Entrez-Gene Id:
WB	H M R Mk	Endogenous	70	Rabbit	#P35637	2521

Product Usage Information

Application	Dilution
Western Blotting	1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

FUS/TLS Antibody recognizes endogenous levels of total FUS/TLS protein.

Species predicted to react based on 100% sequence homology:

Hamster, Bovine, Horse, Guinea Pig

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly272 of human TLS/FUS protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

FUS/TLS (fused in sarcoma/translocated in liposarcoma) was initially identified by investigators as a component of fusion proteins found in a variety of cancers, such as myxoid liposarcoma, acute myeloid leukemia, and Ewing's tumor (1). FUS/TLS fusion with the DNA-binding domain of transcription activators, such as CHOP and ERG, leads to aberrant transcription of target genes that is thought by researchers to lead to tumor development (1-5). FUS/TLS is involved in a wide range of RNA processing events, such as pre-mRNA splicing, mRNA transcription, and miRNA processing (1,6). In addition to its role in RNA metabolism, FUS/TLS maintains genomic stability and co-regulates gene expression by interacting with various transcription factors such as nuclear receptors, YB-1, p65 subunit of NF-κB, TFIID, and RUNX2 (1,6,7). More recently, researchers have found several mutations of FUS/TLS in ALS (amyotrophic lateral sclerosis) and FTLD (frontotemporal lobar degeneration) patients that causes cytoplasmic mislocalization of FUS/TLS (6,8-12).

Background References

1. Yang, S. et al. (2010) *Int J Biochem Cell Biol* 42, 1408-11.
2. Crozat, A. et al. (1993) *Nature* 363, 640-4.
3. Rabbitts, T.H. et al. (1993) *Nat Genet* 4, 175-80.
4. Law, W.J. et al. (2006) *Brief Funct Genomic Proteomic* 5, 8-14.
5. Prasad, D.D. et al. (1994) *Oncogene* 9, 3717-29.
6. Lagier-Tourenne, C. et al. (2010) *Hum Mol Genet* 19, R46-64.
7. Baechtold, H. et al. (1999) *J Biol Chem* 274, 34337-42.
8. Hewitt, C. et al. (2010) *Arch Neurol* 67, 455-61.
9. Vance, C. et al. (2009) *Science* 323, 1208-11.
10. Van Langenhove, T. et al. (2010) *Neurology* 74, 366-71.
11. Da Cruz, S. and Cleveland, D.W. (2011) *Curr Opin Neurobiol* 21, 904-19.
12. Hock, E.M. et al. (2018) *Cell Rep* 24, 987-1000.e7.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

WB: Western Blotting

Cross-Reactivity Key

H: human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Vir:** virus **Mi:** mink **C:** chicken **Dm:** D. melanogaster **X:** Xenopus **Z:** zebrafish **B:** bovine **Dg:** dog **Pg:** pig **Sc:** S. cerevisiae **Ce:** C. elegans **Hr:** horse **GP:** Guinea Pig **Rab:** rabbit **All:** all species expected

Trademarks and Patents

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.